Compounded sermorelin is a pharmacy-prepared formulation of sermorelin acetate, a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It is dispensed by licensed compounding pharmacies against patient-specific prescriptions. In its compounded form, sermorelin is not an FDA-approved finished drug product.
Among growth-hormone-axis peptides ordered through compounding, sermorelin holds a distinctive regulatory footing: a branded sermorelin product was once FDA-approved before its commercial discontinuation. Consolidating sermorelin and sermorelin acetate order records, it ranks as the #13 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. This guide summarizes what the compound is, how providers use it, the forms available, and the regulatory and sourcing questions clinics should weigh.
What Sermorelin Is
Sermorelin acetate is a peptide corresponding to the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH 1–29), the shortest fragment retaining GHRH biological activity. Mechanistically, GHRH acts on GHRH receptors in the anterior pituitary, where it participates in the physiological signaling that governs the secretion of endogenous growth hormone.
Because sermorelin acts upstream at the pituitary rather than supplying growth hormone directly, it is pharmacologically distinct from recombinant human growth hormone products. It is a secretagogue-class peptide — a substance that engages the body's own hormone-releasing pathway. This guide describes that mechanism in neutral, educational terms and does not characterize clinical outcomes.
Historically, sermorelin was studied and marketed for diagnostic evaluation of pituitary growth-hormone secretory capacity and for pediatric growth-hormone deficiency under an FDA-approved brand (Geref). That product was voluntarily discontinued by its manufacturer, and FDA subsequently determined the discontinuation was not for reasons of safety or effectiveness (see Sources). The compounded sermorelin dispensed today is a separate, non-FDA-approved preparation.
How Providers Use It in Practice
Sermorelin is most often ordered by clinicians in longevity, age-management, hormone-optimization, wellness, and men's and women's health practices, alongside some endocrinology-adjacent settings. Providers in these contexts may prescribe sermorelin as part of an individualized plan for select adult patients evaluated for concerns relating to the growth-hormone axis.
The verbs matter here: clinics order it, prescribers evaluate candidates for it, and pharmacies compound it against a specific prescription. Providers are responsible for establishing a legitimate medical purpose and an individualized clinical rationale for each patient, and for documenting that determination. Use of compounded sermorelin outside the historically approved diagnostic and pediatric-deficiency indications falls into off-label prescribing, which is a decision made within the provider-patient relationship rather than something a compounding platform directs or promotes.
Sermorelin is frequently discussed alongside other GHRH analogs and growth-hormone secretagogues within the same practice categories. It should not be described to patients or in marketing as a substitute for growth hormone; the appropriate framing is a distinct peptide with its own mechanism and its own regulatory status.
Forms and Combinations Available Through Compounding
Compounding exists for sermorelin largely because there is no commercially manufactured, FDA-approved sermorelin product on the market, and because prescribers may need a preparation tailored to a particular patient. Compounding pharmacies typically prepare sermorelin as a lyophilized (freeze-dried) powder for reconstitution into a subcutaneous injectable, reflecting the peptide's stability characteristics. Non-injectable presentations — capsules, troches, sublingual tablets, and nasal sprays — are also prepared by some pharmacies when a prescriber documents a patient-specific reason for an alternative route.
Common considerations that lead prescribers to compounding include the need for a specific concentration suited to a patient's plan, a preservative-free preparation for a patient with a documented sensitivity, or a combination product. Some pharmacies offer sermorelin combined with other secretagogue peptides (for example, GHRP-class peptides) in a single vial when a prescriber specifies it. Where such combinations are ordered, the individualized clinical justification for combining the components rests with the prescriber, and the pharmacy should be able to document the rationale and quality controls for each component.
This section intentionally avoids strengths, concentrations, reconstitution volumes, and administration schedules. Those are prescribing and dispensing decisions determined by the clinician and pharmacist for the individual patient, not content for an educational overview.
Regulatory Status and Provider Considerations
As of July 2026, the key regulatory facts for compounded sermorelin are:
- Compounded sermorelin is not FDA-approved. No currently marketed sermorelin drug product carries FDA approval. The compounded preparation has not been reviewed by FDA as a finished product for safety, effectiveness, or manufacturing quality.
- A branded sermorelin product was previously FDA-approved. Sermorelin acetate was marketed under the brand Geref and was later discontinued for commercial reasons. FDA published a determination that the withdrawal was not for reasons of safety or effectiveness — a technical but meaningful point, because it bears on how the substance is treated in the compounding framework.
- Sermorelin has appeared in Category 1 of FDA's interim 503A bulk drug substances list. Category 1 designates substances that FDA's Pharmacy Compounding Advisory Committee (PCAC) and the agency have not finished evaluating and that compounders may continue to use under FDA's interim enforcement policy pending final review. Category 1 status is not an affirmative FDA endorsement, approval, or finding of safety; it reflects a review in progress. FDA has also indicated it stopped assigning newly nominated substances into interim categories after early 2025, while allowing continued use of substances already listed pending final determination (see Sources).
Because sermorelin is compounded from a bulk drug substance, clinics should understand that eligibility rests on the section 503A framework of the Federal Food, Drug, and Cosmetic Act and FDA's interim bulks-list policy, not on any finished-product approval. That footing can change as FDA completes its review, and prescribers ordering the peptide should track the current status rather than rely on its historical approval. Nothing in this article should be read as asserting that compounded sermorelin is equivalent to, or a substitute for, an FDA-approved product.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because compounded sermorelin is a sterile injectable peptide prepared from a bulk substance, sourcing diligence centers on API provenance and sterile-compounding controls. Providers evaluating a pharmacy partner can ask:
- API source and Certificate of Analysis (CoA): Where is the sermorelin acetate API sourced, and can the pharmacy provide a lot-specific CoA documenting identity, purity, and peptide content?
- USP compliance: Does the pharmacy operate in accordance with USP <795> (non-sterile), <797> (sterile compounding), and <800> (hazardous drug handling) as applicable to the preparation?
- Potency and sterility testing: For sterile injectables, does the pharmacy perform or contract potency assays, sterility testing, and endotoxin (pyrogen) testing, and will it share results?
- Beyond-use dating (BUD): How is BUD assigned for the lyophilized product and, separately, after reconstitution, and on what stability basis?
- State licensure and 503A/503B status: Is the pharmacy appropriately licensed in the state(s) where it dispenses, and is it operating as a 503A pharmacy (patient-specific prescriptions) or a registered 503B outsourcing facility? For office stock, 503B registration and FDA cGMP oversight are the relevant considerations.
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed practices with licensed partner compounding pharmacies; the diligence questions above apply regardless of how a clinic reaches its pharmacy.
Frequently Asked Questions
Is compounded sermorelin FDA-approved?
No. As of July 2026, there is no FDA-approved sermorelin drug product on the market, and compounded sermorelin has not been reviewed by FDA as a finished product. A branded sermorelin product (Geref) was previously approved and later discontinued for commercial reasons, but that approval does not extend to today's compounded preparations.
Why is sermorelin still available if the branded product was withdrawn?
FDA determined that the branded product's discontinuation was not for reasons of safety or effectiveness, and sermorelin has been listed in Category 1 of FDA's interim 503A bulk drug substances list, meaning compounders may continue to use it under FDA's interim policy while the agency completes its review.
How should sermorelin be described to patients relative to growth hormone?
Sermorelin is a GHRH analog that acts on the pituitary, which makes it pharmacologically distinct from recombinant human growth hormone. It should not be presented as a growth-hormone substitute or "alternative." Providers are responsible for accurate, individualized communication within the clinical encounter.
What documentation should a prescriber keep?
Prescribers should document the individualized medical rationale for each patient, the legitimate medical purpose, and — for combination products — the justification for each component. This documentation supports the patient-specific basis required under the 503A compounding framework.
Does Category 1 status mean sermorelin is confirmed safe for compounding?
No. Category 1 indicates that FDA and its advisory committee have not completed their evaluation and that use may continue under interim policy. It is neither an approval nor an affirmative safety finding, and the status can change following PCAC review.
Related Reading
- See where sermorelin ranks among the most-prescribed compounded medications
- Compounded NAD+: A Provider's Guide
- 5-Amino-1MQ: A Provider's Guide
Sources
- U.S. Food & Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food & Drug Administration. "Compounding and the FD&C Act — Section 503A." https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fdas-role
- U.S. Food & Drug Administration, Federal Register. "Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness." https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=sermorelin
- U.S. Food & Drug Administration. "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (Guidance for Industry)." https://www.fda.gov/regulatory-information/search-fda-guidance-documents
